The pharmacokinetics of piperacillin, tazobactam and its M1 metabolite were studied in
patients with various degrees of renal impairment after single and multiple intravenous …

The pharmacodynamics of dosage regimens of piperacillin alone or in combination with
tazobactam against piperacillin-resistant or-susceptible bacteria were studied in an in vitro …

Piperacillin-tazobactam is a beta-lactam/beta-lactamase combination antibiotic used in
patients with moderate to severe infection. Dosing of piperacillin-tazobactam requires an …

Objective: To perform a qualitative systematic review of the evidence comparing traditional
strategies against prolonged intermittent or continuous infusion strategies for piperacillin …

Combining tazobactam, a beta-lactamase inhibitor, with the ureidopenicillin, piperacillin,
successfully restores the activity of piperacillin against beta-lactamase producing bacteria …

Piperacillin plasma concentrations are known to vary between critically ill patients. However,
there are no comprehensive data on the variability of antibiotic concentrations within the …

The pathophysiology associated with major burns is complex and subject to a state of flux.
The combination of beta-lactamase inhibitors with powerful penicillins is an interesting and …

Objective Unpredictable pharmacokinetics of antibiotics in patients with life-threatening
bacterial infections is associated with drug under-or overdosing. Therapeutic drug …

Pharmacokinetics were evaluated for piperacillin given as doses of 15, 30 and 60 mg/kg
body weight to 12 healthy volunteers subdivided into three groups which were each given …

Aims To compare the pharmacokinetics of amoxicillin (AMX) in obese and nonobese
subjects, given as single dose 875‐mg tablets. Methods A prospective, single‐centre, open …